Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a “virtual mode” that is pursuing novel biologically-based and disease-modifying therapeutic solutions for a spectrum of neurodegenerative disorders referred to as tauopathies. Dysregulation of the Tau protein is the result of some genetic diseases that currently have no effective treatments, and is largely responsible for the onset of Alzheimer’s disease (AD). By focusing on Tau, we are developing a pipeline of disease-modifying biotherapeutic candidates or products to prevent, delay, or mitigate the underlying dementia or cognitive deficits observed in AD and other related neurodegenerative tauopathies, including:
Over the past two decades, the pharmaceutical industry has spent billions of dollars (U.S.) trying to develop potential therapies for AD targeting the beta-amyloid (Aβ) protein as the cause of the disorder. To date, all have failed in late-stage clinical trials and Tau is now viewed as the much more favorable target, especially since Tau pathology correlates much more closely to the progression of dementia and memory impairment observed in AD than Ab. We at INT are focused on the underlying mechanisms responsible for Tau dysregulation and dementias, and thereby are developing disease-modifying biotherapeutics to prevent, delay, or ameliorate the cognitive decline resulting from tauopathies. In addition, we intent to target an “orphan or niche” genetic disorder, such as FTD, PSP, or CBD, with our anti-Tau therapeutic candidates to gain prospective “fast-track” designation through the FDA with smaller and more cost effective clinical trials. Thus, remaining a virtual company will in turn enable INT to significantly reduce overhead and efficiently advance projects into clinical development.
INT Nominated for the Prestigious 2015 Patrick Soon-Shiong Innovation Awards and Symposium Sponsored by the Los Angeles Business Journal
Innovative NeuroTechnologies, Inc. (INT) has been nominated for the prestigious Los Angles Business Journal’s 2015 Patrick Soon-Shiong Innovation Awards and Symposium to take place on Wednesday, November 18th, 2015 at the Four Seasons Hotel in Beverly Hills, CA. As described by the Los Angeles Business Journal, the program will begin with breakfast and progress through a series of several guest speakers. Attendees will have an opportunity to be inspired by local innovators sharing their expertise on innovation in California. The evening portion of the event will be highlighted by the Patrick Soon-Shiong Innovation Awards dinner, where the individuals and organizations that continue to stretch the boundaries and have proven to be leaders in innovation are honored. INT is certainly thrilled and grateful to be nominated for such an esteemed event and award.
INT Awarded with Phase I SBIR Grant Funding from the National Institute of Health
Innovative NeuroTechnologies, Inc. (INT) in collaboration with James W. Larrick, M.D., Ph.D. of Panorama Research, Inc. (PRI) have been awarded $293,000 Phase I grant from the National Institute of Health (NIH) Small Business Innovation Research (SBIR) program to conduct preliminary “proof-of-concept” animal efficacy studies for the N-terminal Tau monoclonal antibody (i.e., INT-1 mAb) in relevant transgenic mouse models for tauopathies. The group has proposed to develop a novel therapeutic approach for neurodegenerative tauopathies like Alzheimer’s disease (AD) with the use a recombinant adenoassociated viral (AAV) vector to achieve long-term, stable delivery of the N-terminal (INT-1) mAb pass the blood-brain barrier (BBB) and into the affected neurons of the central nervous system (CNS).
Recent Posts / View All Posts
Innovative NeuroTechnologies, Inc. (INT) is focused on the development of novel and disease-modifying Tau-based biotherapeutics for the treatment of Alzheimer’s disease (AD) and other related human tauopathies, such as frontotemporal dementia (FTD or Pick’s disease) and chronic traumatic encephalopathy (CTE). INT is currently in the process advancing multiple monoclonal antibody (mAb) candidates against key epitopes of Tau, which are centrally involved in the early conversion of “normal” physiologic Tau to “pathological” Tau, into Phase I clinical trials within the next two to three years as prospective passive immunotherapies for these neurodegenerative conditions.